Planned pivotal phase III trial of TKM PLK1 for gastrointestinal neuroendocrine tumours (GI-NET)
Latest Information Update: 14 Aug 2013
At a glance
- Drugs TKM PLK1 (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- Sponsors Arbutus Biopharma
- 13 Aug 2013 This trial is expected to start during 2014, subject to favourable date in earlier phase trials, according to a Tekmira Pharmaceuticals media release.
- 13 Aug 2013 New trial record